author-photo

Ana Jaén

28

Papers

168

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

2018 Clinical & Translational Oncology
Show All
- Source
- Cite
- Save
Citations (2)
AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: OS analysis.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Study of the usefulness of angiotensin type 1 receptor (AGTR1) as a possible response predictor in patients with metastatic breast cancer (mBC) subjected to chemotherapy and treatment with bevacizumab (AVALUZ Study).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

2015 Clinical & Translational Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Proliferation Determined by ki67 Marker and pCR in Locally Advanced Breast Cancer Patients Treated with Neo‐adjuvant Chemotherapy

2013 Breast Journal
Show All
- Source
- Cite
- Save
Citations (4)
Acompañar en el ámbito de la familia

2013
- Jesús Morala
- Ana Jaén
Show All
- Source
- Cite
- Save
Citations (0)
Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study

2011 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (23)
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy.

2011 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)